Company profile

John E. Adent
Incorporated in
Fiscal year end
IRS number

NEOG stock data



3 Apr 20
14 Jul 20
31 May 21


Company financial data Financial data

Quarter (USD) Feb 20 Nov 19 Aug 19 May 19
Revenue 99.87M 107.8M 101.42M 109.76M
Net income 12.2M 16.28M 14.65M 15.82M
Diluted EPS 0.23 0.31 0.28 0.3
Net profit margin 12.22% 15.10% 14.45% 14.41%
Operating income 13.04M 18.27M 16.26M 18.73M
Net change in cash -15.64M 10.13M 14.6M -51.89M
Cash on hand 50.77M 66.41M 56.29M 41.69M
Cost of revenue 54.54M 56.78M 53.23M 59.23M
Annual (USD) May 19 May 18 May 17 May 16
Revenue 414.19M 397.93M 361.59M 321.28M
Net income 60.18M 63.15M 43.79M 36.56M
Diluted EPS 1.15 1.21 0.86 0.72
Net profit margin 14.53% 15.87% 12.11% 11.38%
Operating income 68.09M 70.19M 64.95M 56.39M
Net change in cash -41.39M 5.51M 22.31M -10.8M
Cash on hand 41.69M 83.07M 77.57M 55.26M
Cost of revenue 222.27M 211.66M 189.63M 168.21M

Financial data from Neogen earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
14 May 20 James L Herbert Common Stock Gift Dispose G No 64.45 7,800 502.71K 14,072
5 May 20 Lilly Jason Warren Common Stock Sell Dispose S No 64 885 56.64K 10,409
21 Apr 20 James L Herbert Common Stock Gift Dispose G No 66.134 7,600 502.62K 21,872
21 Apr 20 James L Herbert Common Stock Sell Dispose S No 66.134 9,684 640.44K 604
21 Apr 20 James L Herbert Common Stock Sell Dispose S No 66.129 9,684 640.39K 10,288
14 Apr 20 James L Herbert Common Stock Gift Dispose G No 63.23 500 31.62K 29,472
3 Apr 20 James L Herbert Common Stock Sell Dispose S No 63.1 10,000 631K 19,972
3 Apr 20 James L Herbert Common Stock Sell Dispose S No 63.22 10,000 632.2K 29,972
92.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 270 278 -2.9%
Opened positions 26 36 -27.8%
Closed positions 34 27 +25.9%
Increased positions 82 81 +1.2%
Reduced positions 95 96 -1.0%
13F shares
Current Prev Q Change
Total value 11.4B 7.8B +46.2%
Total shares 48.98M 50.13M -2.3%
Total puts 75.4K 50K +50.8%
Total calls 10.9K 14.2K -23.2%
Total put/call ratio 6.9 3.5 +96.5%
Largest owners
Shares Value Change
BLK BlackRock 7.77M $520.31M -2.1%
Brown Capital Management 6.66M $445.96M -1.4%
Vanguard 5.64M $377.68M +1.8%
Wasatch Advisors 2.29M $153.31M -17.5%
Fred Alger Management 1.92M $128.76M -0.1%
STT State Street 1.76M $117.65M +6.1%
Conestoga Capital Advisors 1.66M $110.9M +5.2%
Riverbridge Partners 1.24M $82.75M -0.9%
NEU Neuberger Berman 1.05M $70.29M -2.5%
Bamco 992.28K $66.47M 0.0%
Largest transactions
Shares Bought/sold Change
Norges Bank 0 -934.82K EXIT
Geneva Capital Management 790.23K +790.23K NEW
JHG Janus Henderson 12.87K -652.08K -98.1%
Wasatch Advisors 2.29M -485.32K -17.5%
Mitsubishi UFJ Trust & Banking 441.06K +441.06K NEW
Nuveen Asset Management 210.45K -271.12K -56.3%
Sandhill Capital Partners 0 -253.55K EXIT
FRLG Goldman Sachs 499.37K +187.14K +59.9%
Millennium Management 187.43K +183.14K +4267.9%
BLK BlackRock 7.77M -163.24K -2.1%

Financial report summary

Management Discussion
  • Neogen’s results reflect an 11% increase in international sales in fiscal 2019 compared to the prior year. We continue to focus on increasing our presence and market share throughout the world, while also integrating recent international acquisitions into our product portfolio. Sales increases for fiscal 2019 compared to the prior year are as follows for each of our international locations:
  • Currency translation had a negative impact of approximately $8.0 million on revenues recorded in foreign currencies during fiscal 2019, as the U.S. dollar strengthened against all the currencies in the countries in which we conduct business. The revenue increase in Europe was led by a 14% increase in sales of genomics services, primarily in the porcine and bovine markets. Deoxynivalenol (DON) test kit sales also increased 19% due to increased testing after a DON outbreak in France’s wheat crops in the fall of calendar 2018. Sales at Quat-Chem increased 17%, due to increased sales coverage and the introduction of new products into their markets.
  • After adjusting for a 15% devaluation of the real against the dollar, sales in Brazil increased 16%, led by a 90% increase in sales of natural toxins test kits, as we gained significant new business from customers testing for the presence of aflatoxin in corn. Sales of forensic test kits, used for required drug testing of commercial drivers in Brazil, increased significantly due to business that shifted from U.S. labs to labs in Brazil and increased demand from commercial laboratories located in Brazil. Neogen Latinoamerica grew revenues by 13%, with gains across most product lines, in particular mycotoxins and culture media, and increased sales in both Mexico and Central America.
Content analysis ?
8th grade Avg
New words: Abtek, agency, Ai, Argentina, Argentine, attention, begun, borrowingswill, Brexit, Cell, chain, Chile, Chilena, communicable, delayed, Diessechem, disorderly, disrupted, disruption, drove, economy, ensure, exceed, experienced, feed, frame, high, Hubei, insured, Italy, lack, largest, Latin, liquidity, Liverpool, Magiar, Melbourne, microbiology, Milan, Montevideo, Nicaragua, noncancelable, pandemic, personnel, plant, predicted, pretax, Province, raw, rebate, regulatory, rental, resolved, Robust, Santiago, spread, Srl, strain, supply, throughapplication, travel, upward, Uruguay, Uruguayan, weakened, widespread, Wuhan
Removed: aflatoxin, application, country, gain, Item, permitted, reduction, weak